INSM: Brinsupri $517M 1H26 and Positive TPIP Phase 2b Reinforce Bull Case, but Valuation and Cash Burn Persist

What happened

Insmed's Brinsupri launch continues to scale, with 1H 2026 revenue of $517 million, nearly reaching the midpoint of the company's full-year guidance of at least $1.0 billion in just two quarters, validating the blockbuster trajectory highlighted in earlier reports. Newly released TPIP Phase 2b data exceeded expectations, establishing a second potential blockbuster franchise with four planned Phase 3 indications that could collectively address a $6+ billion peak sales opportunity, partially offsetting the earlier hidradenitis suppurativa setback. The stock's pullback from its 2025 high of around $211 to below $130 (based on the article's 'discount to recent highs' remark) reflects lingering concerns over sharply rising SG&A and persistent operating cash burn, as detailed in the first-quarter 2026 10-Q. Management's reiterated guidance and the latest pipeline news appear to have shifted the market's focus back to top-line growth, but the next two quarterly reports remain critical to confirm sequential Brinsupri gains and expense discipline. Overall, the fundamental picture has improved with a stronger commercial franchise and a more credible pipeline, yet the stock's valuation still embeds significant execution risk given its heavy reliance on future revenue acceleration and cost control.

Implication

The strong Brinsupri performance in the first half of 2026 reduces the likelihood of a near-term guidance miss and supports the base-case valuation of around $110, while the TPIP Phase 2b success adds upside optionality that could push fair value toward the $145 bull scenario if Phase 3 enrollment progresses smoothly. However, the company still burns over $200 million in cash per quarter, and the stock trades at a rich multiple of sales, leaving little room for operational missteps. Investors should watch for signs of operating leverage in the upcoming Q2 and Q3 10-Qs, specifically whether SG&A growth decelerates below revenue growth and whether Brinsupri continues to add patients organically rather than from the pre-launch backlog. A timely Arikayce sNDA submission later in 2026 remains another key catalyst that could further support the stock, but any slip in these milestones would likely trigger a sharp de-rating. For now, the balance of evidence tilts constructive, but position sizes should reflect the binary nature of the upcoming catalysts.

Thesis delta

The positive TPIP Phase 2b results represent a notable upgrade to the pipeline's risk/reward, adding a third high-value asset alongside Brinsupri and Arikayce and partially repairing credibility after the hidradenitis suppurativa failure. However, the core thesis concerns—aggressive SG&A spending and high cash burn—remain unresolved, and the stock's valuation already prices in substantial future success. The thesis shifts from a cautious 'potential buy' to a more balanced view where the upside scenario has become more tangible, but the entry point and financial discipline are now the primary swing factors.